DCi

DCi Biotech guides global pharmaceutical, medical device and biotech companies through the complicated processes required to bring cell therapies to market. Our business advice addresses cell therapy commercialization issues, such as meeting Regulatory requirements, obtaining reimbursement, minimizing cost of goods, and optimizing clinical trial design.

Our distinctive expertise allows us to evaluate and advise on organic opportunities, as well as perform due diligence on external investments, including placements, licensing, and acquisitions. We also work with management teams to develop business plans and presentations for investors.

DCi Biotech is a unique consulting practice. It combines extensive biotech and pharmaceutical industry experience with an understanding of the science and medicine behind cell-based therapeutics—a major asset for decision makers seeking business advice in regenerative medicine.
» Read More

	August 09, 2010 DCi at World Stem Cell Summit » More
	August 08, 2010 DCi Biotech at CHI's BioBanking Summit » More
	July 06, 2010 AlloCure, With Stem Cell therapy for Kidney Failure, Arrives in New England with New CEO » More
	July 01, 2010 Pharma's R&D Focus Shifting to Stem Cells » More
	June 30, 2010 Celgene Corporation to Acquire Abraxis BioSciences Inc. » More
	June 30, 2010 Stem cell therapy may provide new approach to fight infection » More
	May 30, 2010 DCi Biotech Continues Sponsorship of ISCT Global Regulatory Perspectives Workshop » More
	May 25, 2010 T2cure's Mid-Stage Somatic Stem Cell Product Receives EMEA Quality Certification » More
	May 21, 2010 Biotech's $1 Billion Tax Credits Are Up for Grabs! OK, Now Everybody Relax » More
	August 10, 2009 DCi Biotech at World Stem Cell Summit » More
	May 04, 2009 Funding and Reimbursement Sessions at ISCT 2009 » More

» News archive